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INTRODUCTION:
Catastrophic
antiphospholipid syndrome (CAPS) is a rare
complication occurring in 1% of patients
with Antiphospholipid Syndrome (APS). [4]
It presents with widespread intravascular
thrombosis leading to the failure of multiple
organs (commonly the kidneys, lungs, brain,
heart, and others. These thromboses are
caused by antiphospholipid antibodies which
are thought to induce a hypercoagulable and
prothrombotic state by acting on endothelial
cells, platelets, and fibrinolysis. Furthermore,
the autoantibodies act to activate the
complement system and ramp up the immune
system creating a hyper-inflammatory state
which explains why most patients with CAPS
will also meet criteria for SIRS. [1]
Diagnosis of CAPS remains challenging due
to its clinical overlap with other thrombotic
microangiopathies. [2] However, diagnostic
criteria include but are not limited to the
involvement of three or more organs,
development of the signs and symptoms
contemporaneously within one week, biopsy
demonstrating microangiopathy, and two
separate
serological
findings
of
antiphospholipid antibodies separated by six
weeks. Generally, a diagnosis of Definite
CAPS is made if all the criteria are met but if
only three are met the diagnosis is Probable
CAPS. [1,2,3] Serology can reveal
anticardiolipin, Lupus Anticoagulant, anti_________________
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β2-glycoprotein I, and antinuclear antibodies.
[1]
Management
with
anticoagulation,
corticosteroids, plasmapheresis, IVIg, and
aspirin resulted in a decline in the mortality
rate from a half to a third of patients.
Cyclophosphamide produces greater survival
benefit in patients with SLE. Refractory cases
can be treated with rituximab or eculizumab
[4]. Rituximab is thought to be a possible
alternative treatment due to its ability to
reduce the detrimental autoantibodies and
cytokines speculated to be involved in CAPS.
[5] Here, we report a case of Probable CAPS,
in the setting of SLE, treated with rituximab
in addition to most of the standard treatments
(plasmapheresis, IVIg, glucocorticoids).
CASE REPORT: Previously healthy 18 year
old African female college student initially
presented to an outside hospital with 2 week
history of low grade fevers, erythematous
rash with blisters on her hands, feet, and face,
diarrhea (15 bowel movements a day),
decreased appetite with weight loss,
shortness of breath, and worsening fatigue
and weakness. She was diagnosed with Hand
Foot Mouth disease and discharged 3 days
later. Three weeks later, her condition
worsened and she was admitted to the same
hospital. Labs at the OSH were significant
for: hgb 10.5, plt 114, PT 16.75, INR 1.58,
Na 130, tbili 10, dir bili 8.4, ALP 312, AST
1263, ALT 187, lactate 1.7, HIV neg, CRP <
0.29, RF < 10. The patient experienced a
tonic-clonic seizure 4 days after admission
and was given Ativan and Keppra. She is up
to date on her immunizations and had no
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recent sick contacts. She was born in Nigeria
and moved to the US two and a half years ago
for college and has not left the US since then.
After the seizure at the OSH, the patient was
taken by family to our ED. She was lethargic
and unresponsive in her car and was brought
in by ED staff, patient was tachycardic up to
131, tachypneic up to 50, and hypotensive
80/50. She was given 3 liters of IVF with
transient improvement in BP. Due to patient's
worsening mental status and desaturation,
she was intubated and required vasopressors
for hypotension. Labs were significant for
hgb 7, plt 78, INR 4.3, Na 134, K 3.4, Cl 112,
HCO3 8, BUN 31, Cr 1.7, alb 1.4, AST 1102,
ALT 156, alk phos 267, tbili 6.7, CRP 9.3,
lactate 5.4, procal 73, UA with 74 WBC, 259
RBC, 5 granular casts on sediment, and UPC
of 8338 mg/g. CXR showed diffuse bilateral
interstitial and alveolar opacities. CT chest
showed patchy bilateral consolidation,
pleural effusion and axillary/supraclavicular
LAD. CT head had minimal prominence of
the temporal horns and third ventricle. CT
abdomen showed hepatomegaly, inguinal
LAD, and small amount of free fluid in the
abd/pelvis.
Due to worsening respiratory status, patient
required
intubation
and
mechanical
ventilation. Her pulmonary edema, elevated
cardiac enzymes, and renal function (urine
output and creatinine) worsened even with
gentle diuresis so she required dialysis. Her
hospital course was complicated by MSSA
bacteremia (on HD 8), MSSE bacteremia (on
HD 32), C. krusei candidemia (on HD 37),
and CMV Colitis (on HD 46). TEE was
negative for any other structural or valvular
abnormalities. She was treated with
vancomycin, pip-tazo, cefepime, cefazolin,
ciprofloxacin, metronidazole, fluconazole,
voriconazole, micafungin, valganciclovir,
and
acyclovir
during
admission.
Autoimmune work-up was positive for
ANA+ (homogeneous 1:640 titer), dsDNA
96, Chromatin >8, Smith 1.9, Sm RNP 2.5,
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RNP 6.6, Lupus Anticoagulant, Beta-2glycoprotein IgA, decreased C3/C4 levels,
and elevated ESR/CRP. PBS showed 6-9
schistocytes/hpf. Additional lab work
showed consistent elevation of PT/PTT, LD
(1494), normal fibrinogen, haptoglobin, and
slight decreased ADAMST13 activity (36%).
On HD6, MRI Brain that showed interval
development
of
several
significant
intraparenchymal hematomas with mild mass
effect (largest in left frontal lobe is 26cc with
3 mm midline shift) and intraventricular
extension suggestive of severe coagulopathy.
Pt was transfused with platelets and pRBC's
and started on hypertonic saline boluses.
Patient was treated for Probable CAPS, in the
setting
of
SLE,
with
daily
hydroxychloroquine,
daily
methylprednisolone 80 mg, 5 cycles of
plasmapheresis, and 3 cycles of rituximab
(beginning on HD 16; 375mg/m2 each dose).
Anticoagulation was held in the setting of the
patient’s intracerebral hemorrhage and
frequent bleeding from tracheostomy site.
Renal biopsy was not performed since the
patient
had
thrombocytopenia
and
leukocytosis. Given her positive anti-dsDNA
antibody, microscopic hematuria, nephrotic
range proteinuria on UA, and poor renal
function, patient was treated with
mycophenolate mofetil for Lupus Nephritis.
On HD 19, pt had a seizure-like episode and
Keppra was started. vEEG showed diffuse
background changes and no evidence of
seizure. Contrast CT Head was negative for
abscesses or masses. The patient gradually
began showing signs of improvement with
the ability to follow simple commands and
improvement of laboratory values. Repeat
CT head demonstrated improving edema and
resolved midline shift. On HD 52, patient was
taken off of hemodialysis with good renal
function and only required hemodialysis on
HD 58 due to hyperkalemia.
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L hand rash
R hand rash

R hand rash

R elbow discoid rash

T2 AX MRI Brain
R lower lip mucosal erosion
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Noncon CTH

CT Chest on admission with patchy opacities
and bilateral pleural effusions noted
DISCUSSION: CAPS is a devastating
syndrome that disproportionately affects
women at higher rates than men (72% of
CAPS occur in women). Most cases are
precipitated by infection, operations,
stopping anticoagulants, complications of
pregnancy, and malignancy. Approximately
half of patients with CAPS have an
autoimmune disorder and 40% have SLE
which is a poor prognostic factor. [6] Since
there was no tissue biopsy demonstrating
MAHA, the diagnosis was Probable CAPS.
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The kidneys are the most commonly involved
organ (greater than two thirds of CAPS cases)
leading to acute kidney failure, proteinuria,
hematuria, hypertension. Other frequently
involved organs are the lungs (64%), CNS
(62%), heart (51%), and skin (50%). [1] Our
patient exhibited involvement of all these
organs and the liver on initial presentation;
furthermore, all of her signs and symptoms
appeared within the same timeframe. The
most common laboratory findings are
antiphospholipid antibodies (especially
Anticardiolipin
IgG
and
Lupus
anticoagulant), ANA, and thrombocytopenia.
Because CAPS causes microangiopathy,
schistocytes and hemolytic anemia can also
be seen. All of these laboratory findings,
except anticardiolipin IgG, were seen in this
case. [1,2] CAPS is commonly treated with
anticoagulation,
antiplatelet
agents,
corticosteroids, plasmapheresis, and IVIg.
Plasmapheresis and IVIg remove the
antiphospholipid antibodies which are
thought to be the causative agents of CAPS.
Anticoagulation and antiplatelet agents
counteract
the
hypercoagulable
and
prothrombotic state. Corticosteroids relieve
the ongoing inflammatory processes caused
by the activation of the complement
pathways. Additionally, biologic therapies
have been recommended for the treatment of
refractory CAPS. Rituximab, an antibody
against CD20, is thought to reduce B cells
leading to decreased antiphospholipid
antibody and cytokine levels. Eculizumab is
an antibody that inhibits the terminal
complement pathway thereby decreasing the
amount of tissue injury and inflammation.
Case reports and CAPS registry have shown
resolution of CAPS refractory to standard
management after use of eculizumab or
rituximab. [5] Herein, we report the
improvement of Probable CAPS upon adding
rituximab to the therapeutic regimen.
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CONCLUSIONS: This is a life-threatening
syndrome and as such a high index of
suspicion and early diagnosis are required in
order to reduce patient morbidity and
mortality. [1-3] Standard treatments with
proven survival benefit are anticoagulation,
antiplatelet
agents,
corticosteroids,
plasmapheresis, and IVIg. [4] SLE is a worse
prognostic factor for CAPS but these patients
can be treated with cyclophosphamide with
improved survival. [6] Case reports have
shown a role for additional biologic therapies
like eculizumab and rituximab. [4,5,7]

7. Chitalia A, Swoboda D, et al. (2016)
Management of catastrophic
antiphospholipid syndrome with
eculizumab. Blood, 128:2603.
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